Luoxin Pharmaceuticals Group Stock Co Ltd (002793) — Net Asset Quality Index
Luoxin Pharmaceuticals Group Stock Co Ltd (002793) has a Net Asset Quality Index of 32.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.57 Billion minus total liabilities of CN¥2.39 Billion yields net assets of CN¥1.18 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 002793 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Luoxin Pharmaceuticals Group Stock Co Ltd Net Asset Quality Index Over Time (2011–2025)
This chart shows how Luoxin Pharmaceuticals Group Stock Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the index stands at 32.9%, representing net assets of CN¥1.18 Billion against total assets of CN¥3.57 Billion CNY. See working capital position of Luoxin Pharmaceuticals Group Stock Co Lt to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Luoxin Pharmaceuticals Group Stock Co Lt market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 33.2% | CN¥1.24 Billion | CN¥3.73 Billion | CN¥2.49 Billion | ▼ -0.5 pp |
| 2024 | 33.7% | CN¥1.46 Billion | CN¥4.34 Billion | CN¥2.88 Billion | ▼ -16.6 pp |
| 2023 | 50.3% | CN¥2.57 Billion | CN¥5.12 Billion | CN¥2.54 Billion | ▲ +9.5 pp |
| 2022 | 40.8% | CN¥3.31 Billion | CN¥8.11 Billion | CN¥4.80 Billion | ▼ -9.1 pp |
| 2021 | 49.9% | CN¥4.74 Billion | CN¥9.50 Billion | CN¥4.76 Billion | ▼ -6.5 pp |
| 2020 | 56.3% | CN¥4.35 Billion | CN¥7.72 Billion | CN¥3.37 Billion | ▲ +3.2 pp |
| 2019 | 53.1% | CN¥3.96 Billion | CN¥7.46 Billion | CN¥3.50 Billion | ▼ -11.8 pp |
| 2018 | 64.9% | CN¥909.89 Million | CN¥1.40 Billion | CN¥491.85 Million | ▼ -19.0 pp |
| 2017 | 83.9% | CN¥754.19 Million | CN¥898.93 Million | CN¥144.74 Million | ▼ -2.0 pp |
| 2016 | 85.9% | CN¥698.33 Million | CN¥812.89 Million | CN¥114.56 Million | ▲ +24.1 pp |
| 2015 | 61.8% | CN¥339.50 Million | CN¥549.60 Million | CN¥210.10 Million | ▼ -8.7 pp |
| 2014 | 70.4% | CN¥315.46 Million | CN¥447.86 Million | CN¥132.40 Million | ▲ +1.2 pp |
| 2013 | 69.2% | CN¥251.50 Million | CN¥363.30 Million | CN¥111.80 Million | ▲ +14.0 pp |
| 2012 | 55.2% | CN¥205.54 Million | CN¥372.31 Million | CN¥166.77 Million | ▼ -0.6 pp |
| 2011 | 55.8% | CN¥151.87 Million | CN¥271.94 Million | CN¥120.07 Million | — |